ClinicalTrials.gg

Program

TQA3038

A development code. Also written as “TQA3038 injection”.

In Sino Biopharmaceutical's pipeline, siRNA. Its studies are mostly in Hepatitis B, Chronic, led by Sino Biopharmaceutical.

Furthest: phase 1, since Oct 11, 20231 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical11 open or runningphase 1since Oct 11, 2023Oct 11, 2023none ahead
  • Named in Sino Biopharmaceutical’s own pipeline as TQA3038, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 11, 2023First study: phase 1 study in Hepatitis B, ChronicFirst studyNCT06085053 · 54 planned · China

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“siRNA”the company's pipeline, read by Claude · source

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06085053Hepatitis B, Chronic · China1RecruitingDec 202454

How it is read

Names in the registry

  • “TQA3038 injection”, 1 entry

Codes read as this program: TQA3038.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.